Glycopyrronium bromide

The Pre-filled Syringes Market size to grow by USD 3.51 billion from 2022 to 2027| North America is estimated to contribute 36% to the growth of the global market - Technavio

Retrieved on:

Tuesday, November 14, 2023

By geography, the market is segmented by North America, Europe, Asia, and the Rest of the World (ROW).

Key Points:

By geography, the market is segmented by North America, Europe, Asia, and the Rest of the World (ROW).
North America is estimated to contribute 36% to the growth of the global market during the forecast period.
The pre-filled syringes market is fragmented, and the vendors are deploying organic and inorganic growth strategies to compete in the market.
The market share growth by the glass pre-filled syringes segment will be significant during the forecast period.

Medexus Secures Public Reimbursement for Cuvposa® in Quebec

Retrieved on:

Wednesday, February 1, 2023

Public, RAMQ, TSX, Caregiver, Cerebral palsy, Government, Hospital, Hypersalivation, Dysphagia, Patient, Partnership, Health insurance, Glycopyrronium bromide

TORONTO and CHICAGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) wishes to inform investors that the company has reached an agreement with the provincial government of Quebec for government-sponsored coverage of Cuvposa (glycopyrrolate oral solution 1mg/5mL).

Key Points:

TORONTO and CHICAGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) wishes to inform investors that the company has reached an agreement with the provincial government of Quebec for government-sponsored coverage of Cuvposa (glycopyrrolate oral solution 1mg/5mL).
Cuvposa will be listed for public reimbursement on the Public Prescription Drug Insurance Plan of the Régime de l’Assurance Maladie du Québec, or RAMQ, starting February 1, 2023.
Cuvposa is indicated in Canada to reduce chronic severe drooling in pediatric patients 3 to 18 years of age with neurologic conditions associated with problem drooling, such as cerebral palsy.
“We are therefore proud to make Cuvposa available to more patients in Quebec through this new partnership with the Quebec government.

DoseData Launches Real-time Analytics on 315 Drugs to Provide More Transparency Into the Pharmaceutical Supply Chain

Retrieved on:

Monday, April 25, 2022

Until now, no datasets on the market have offered insight into this crucial part of the pharmaceutical supply chain.

Key Points:

Until now, no datasets on the market have offered insight into this crucial part of the pharmaceutical supply chain.
Because DoseData sources information directly from hospitals, the company is able to provide daily updates regarding all relevant data.
By relying solely on months-old sales data, pharmaceutical companies have historically been looking in the rearview as they try to navigate an ever-changing and unpredictable supply chain.
Were thrilled to bring DoseData to the market and offer unparalleled transparency to the healthcare and pharmaceutical ecosystem, said Tara Hanusa, Data Product Manager at DoseData.

Propeller Health Sensor to Be Co-Packaged With Recently Approved Enerzair® Breezhaler® Asthma Medication in Europe

Retrieved on:

Tuesday, July 7, 2020

Data management, Health, Technology, Hospitals, Software, General Health, Chemical compounds, Drugs, Health, Respiratory therapy, Muscarinic antagonists, RTT, Pregnanes, Progestogens, Mometasone, Indacaterol, Glycopyrronium bromide, Novartis

Propeller Health today announced a collaboration with Novartis to co-package the Propeller digital health platform with Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]), a recently approved Novartis medication developed to treat uncontrolled asthma.

Key Points:

Propeller Health today announced a collaboration with Novartis to co-package the Propeller digital health platform with Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]), a recently approved Novartis medication developed to treat uncontrolled asthma.
View the full release here: https://www.businesswire.com/news/home/20200706005585/en/
An industry first: Propeller Health digital health solution packaged and prescribed with Enerzair Breezhaler inhaler by Novartis.
Enerzair Breezhaler and Propeller sensor and app received approval from the European Commission on in July and will launch across Europe starting in 2020.
Healthcare professionals in Europe will have the option to prescribe Enerzair Breezhaler with or without the companion digital health platform.

Sosei Heptares Announces That the COPD Treatment Ultibro® Breezhaler® has been Included in the National Reimbursement Drug List in China

Retrieved on:

Thursday, November 28, 2019

Drugs, Chemical compounds, Muscarinic antagonists, Organic compounds, Combination drugs, Indacaterol/glycopyrronium bromide, Quaternary ammonium compounds, Tertiary alcohols, Glycopyrronium bromide, Chronic obstructive pulmonary disease, Indacaterol, COPD: Journal of Chronic Obstructive Pulmonary Disease

TOKYO and LONDON, Nov. 28, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included in the 2019 National Reimbursement Drug List (NRDL) in China for the treatment of chronic obstructive pulmonary disease (COPD).

Key Points:

TOKYO and LONDON, Nov. 28, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included in the 2019 National Reimbursement Drug List (NRDL) in China for the treatment of chronic obstructive pulmonary disease (COPD).
The list is approved nationally with the aim of providing basic medical coverage to China's population of 1.4 billion.
Glycopyrronium bromide and certain use and formulation intellectual property were exclusively licensed to Novartis in April 2005 by Sosei Heptares and Vectura.
"Sosei Heptares" is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

Sosei Heptares Announces That the COPD Treatment Ultibro® Breezhaler® has been Included in the National Reimbursement Drug List in China

Retrieved on:

Thursday, November 28, 2019

TOKYO and LONDON, Nov. 28, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included in the 2019 National Reimbursement Drug List (NRDL) in China for the treatment of chronic obstructive pulmonary disease (COPD).

Key Points:

TOKYO and LONDON, Nov. 28, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included in the 2019 National Reimbursement Drug List (NRDL) in China for the treatment of chronic obstructive pulmonary disease (COPD).
The list is approved nationally with the aim of providing basic medical coverage to China's population of 1.4 billion.
Glycopyrronium bromide and certain use and formulation intellectual property were exclusively licensed to Novartis in April 2005 by Sosei Heptares and Vectura.
"Sosei Heptares" is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

Dermira to Report Third Quarter 2019 Results and Host Conference Call on Tuesday, November 5, 2019

Retrieved on:

Tuesday, October 29, 2019

Biotechnology, Pharmaceutical, Health, Chemical compounds, Life sciences, Organic compounds, Hyperhidrosis, Thoracic surgery, Muscarinic antagonists, Glycopyrronium bromide, Dermatology, Perspiration, Biopharmaceutical

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions.

Key Points:

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions.
Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology products.
The companys approved treatment, QBREXZA (glycopyrronium) cloth, is indicated for pediatric and adult patients (ages 9 and older) with primary axillary hyperhidrosis (excessive underarm sweating).
Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD.

Dermira to Report Second Quarter 2019 Results and Host Conference Call on Wednesday, August 7, 2019

Retrieved on:

Wednesday, July 31, 2019

Biotechnology, Other Health, Health, Pharmaceutical, Chemical compounds, Organic compounds, Branches of biology, Hyperhidrosis, Thoracic surgery, Muscarinic antagonists, Glycopyrronium bromide, Perspiration, Dermatology, Axilla

Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology products.

Key Points:

Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology products.
The companys approved treatment, QBREXZA (glycopyrronium) cloth, is indicated for pediatric and adult patients (ages 9 and older) with primary axillary hyperhidrosis (excessive underarm sweating).
Dermira also has early-stage research and development programs in other areas of dermatology.
Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD.

Dermira to Present at the Raymond James Life Sciences and MedTech Conference

Retrieved on:

Tuesday, June 11, 2019

Health, Biotechnology, Pharmaceutical, Chemical compounds, Organic compounds, Branches of biology, Hyperhidrosis, Thoracic surgery, Muscarinic antagonists, Glycopyrronium bromide, Axilla, Perspiration, Dermatology

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present at the Raymond James Life Sciences and MedTech Conference in New York on June 18, 2019 at 2:25 p.m.

Key Points:

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present at the Raymond James Life Sciences and MedTech Conference in New York on June 18, 2019 at 2:25 p.m.
The companys approved treatment, QBREXZA (glycopyrronium) cloth, is indicated for pediatric and adult patients (ages 9 and older) with primary axillary hyperhidrosis (excessive underarm sweating).
Dermira also has early-stage research and development programs in other areas of dermatology.
Therefore, investors should monitor Dermiras website, LinkedIn page, Instagram and Twitter accounts in addition to following itsSECfilings, news releases, public conference calls and webcasts.

Sosei Heptares Notes That a Valid Marketing Authorization Application For QVM149, a Potential New Inhaled Combination Therapy For Asthma, Has Been Filed With the European Medicines Agency

Retrieved on:

Friday, May 24, 2019

Chemical compounds, Organic compounds, Drugs, Muscarinic antagonists, Cyclopentanes, Glycopyrronium bromide, Pyrrolidines, Novartis, Sosei, Vectura Group

The MAA filing, which was previously planned for Q4 2019, has triggered a US$2.5 million payment to Sosei Heptares from Novartis.

Key Points:

The MAA filing, which was previously planned for Q4 2019, has triggered a US$2.5 million payment to Sosei Heptares from Novartis.
Glycopyrronium bromide and certain intellectual property relating to its use and formulation were exclusively licensed to Novartis in April 2005 by Sosei Heptares and Vectura Group PLC (LSE: VEC).
QVM149 is currently being investigated in Phase III/IIIb studies (IRIDIUM1 and ARGON2), which are expected to complete in Q3 2019.
"Sosei Heptares" is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).